08:49 AM EDT, 09/25/2024 (MT Newswires) -- Kymera Therapeutics ( KYMR ) said Wednesday preclinical data shows its potential Investigational New Drug KT-621 effectively reduces TH2 inflammation in models of atopic dermatitis and asthma.

In preclinical studies, KT-621, a potential once daily oral treatment for TH2 driven allergic and atopic diseases, fully blocked key drivers of allergic and atopic inflammation, with potency comparable to or greater than dupilumab, the company said.

Kymera said it has completed its Investigational New Drug-enabling studies and plans to initiate a phase 1 trial for KT-621 in H2, with data expected in H1 2025.